By Eric Sagonowsky
Merck's positive data for oral COVID-19 antiviral molnupiravir continue to pay off in a big way. On Wednesday, just a day after unveiling a $1 billion sale order to the U.S., the company disclosed another major supply deal.
read more
By Nick Paul Taylor
Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement on a symptom scale. But the stock fell in the wake of the news amid discussion of adverse events and durability.
read more
By Paige Minemyer
Virta will be available as an option beginning in January 2022, according to an announcement. The solution aims to reverse Type 2 diabetes through personalized nutrition therapy and around-the-clock remote medical care.
read more
By Dave Muoio
Tenet is spending big to gain a majority stake in 92 ASCs about a year after inking a similar deal with the ambulatory care company. The deal is set to grow its high-margin USPI subsidiary to 440 facilities across 35 states and opens the door to ownership of at least 50 more de novo ASCs in the next five years.
read more
By Angus Liu
Eli Lilly’s Olumiant has been dragged into a classwide safety review of JAK medicines that originated from Pfizer’s Xeljanz. Hoping to convince doctors that its offering doesn’t share the problems at the same magnitude, the Indianapolis pharma is turning to long-term data.
read more
By Robert King
Nearly 60% of health systems plan to get into a Medicare Advantage risk-based payment model as part of a growing trend towards "payvider" models, a new survey finds.
read more
By Ben Adams
The future of cell therapy is allogenic, it seems, as Poseida has decided to back away from work on its autologous candidate.
read more
By Angus Liu
The NaV1.7 ion channel is expressed in some neurons and plays a critical role in sensing pain, but suppressing it head-on has proven tricky. A drug that blocks the channel through two related proteins relieved pain in several animal models, a University of Arizona team reported, and Regulonix has licensed it for development.
read more
By Angus Liu
After an FDA cold shoulder, FibroGen and partner AstraZeneca still aim to pave a way to market for anemia therapy roxadustat—even if it means conducting another clinical trial. The two companies are now betting the drug’s U.S. future on an upcoming meeting with the FDA.
read more
By Conor Hale
That deal represents a healthy return for Atos’ private equity owner, Paris-based PAI Partners, which bought the Swedish company in 2016 for about €850 million.
read more
By Andrea Park
After pivoting during the coronavirus pandemic from providing whole-genome sequencing and genetic counseling to developing COVID-19 tests and coordinating vaccine delivery, Color has now set its sights on building a population health infrastructure that makes screening, diagnostics and early treatment more accessible to all patients.
read more
By Nick Paul Taylor
Immatics has delivered evidence that its TCR-engineered cell therapies can move the needle in solid tumors, revealing 50% of heavily pretreated patients responded to its candidate despite taking less than the target dose. The challenge now? To improve the durability of the responses.
read more
